# RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

> **NCT02829957** · PHASE2,PHASE3 · COMPLETED · sponsor: **Indiana University** · enrollment: 19 (actual)

## Conditions studied

- Venous Thromboembolism
- Menstruation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT02829957
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-02-13
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02829957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02829957, "RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02829957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*